Skip to content

A pragmatic randomized controlled trial for Lingnan's Shugan Tiaoshen integrated program of acupuncture and moxibustion in the treatment of moderate depressive disorder

A pragmatic randomized controlled trial for Lingnan's Shugan Tiaoshen integrated program of acupuncture and moxibustion in the treatment of moderate depressive disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075922
Enrollment
Unknown
Registered
2023-09-19
Start date
2023-09-19
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive disorder

Interventions

Integrated acupuncture group:Integrative acupuncture therapy
Drug group:Oral Sertraline

Sponsors

Guangdong Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The results were in accordance with the diagnostic criteria of traditional Chinese and Western medicine; 2. Age 18-65 years old, junior high school or above; 3. The 17-item Hamilton Depression Scale (HAMD-17) scores were more than 17 and less than 24; 4. They signed informed consent and volunteered to participate in this study. 5. Right-handedness (For use in The Second Affiliated Hospital, Guangzhou University of Chinese Medicine only) Only those who meet the above 5 items can be included in the study.

Exclusion criteria

Exclusion criteria: 1. Those with suicidal tendency; 2. Previous diagnosis of mental retardation, schizophrenia, bipolar disorder, substance abuse (such as alcohol dependence) or other mental disorders; 3. History of epilepsy, family history of strong positive epilepsy, history of brain organic diseases and severe somatic diseases; 4. Those who are taking antidepressants within 6 weeks (including 6 weeks); 5. Patients undergoing other psychotherapy 6. Pregnancy, pregnancy preparation, or lactation; 7. Patients with skin lesions or skin diseases, severe diabetes mellitus, tumor and important organ dysfunction, or severe internal diseases such as liver, kidney, cardiovascular, endocrine, respiratory, and hematopoietic systems; 8. Patients with contraindications to MRI such as pacemakers, cardiac stents, claustrophobia, etc. 9. Patients with other central or peripheral neuropathy. Those who met any of the above criteria were excluded from the study.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale 17-item version (HAMD-17);

Secondary

MeasureTime frame
Patient Health Questionnaire 9-item version (PHQ-9);Hamilton Anxiety (HAMA) scales;Pittsburgh Sleep Quality Index (PSQI);Stroop task;

Countries

China

Contacts

Public ContactWenbin Fu

Guangdong Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital, Guangzhou University of Chinese Medicine)

fuwenbin@gzucm.edu.cn+86 176 6508 8048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026